Medical industry "veteran" Yangzijiang Pharmaceuticals New Bureau

In the 13th Five-Year Plan for the Development of Traditional Chinese Medicine, the Chinese medicine industry has been promoted to the status of "an important pillar industry of the national economy". For this emerging pillar industry, governments at all levels continue to introduce incentives, some pharmaceutical companies are trying to redeveloy this new blue sea and speed up the market layout. But there are also many pharmaceutical companies in the face of industry development difficulties. How to get a glimpse of the trend and confusion of the development of Chinese medicine? As a "veteran" of the pharmaceutical industry that has topped the top 100 list of China's pharmaceutical industry for four consecutive years, the practice of Yangzijiang Pharmaceutical Group may provide some clues.Good attack on the development of Traditional Chinese medicine to meet the strong heart agent
Recently, the 2018 (35th) National Pharmaceutical Industry Information Conference was held, the meeting revealed the "2017 China's top 100 pharmaceutical industry list" once again caused widespread concern. It is reported that the minimum threshold for 2017 to be included in the list of top 100 enterprises has been raised from 2.4 billion yuan in 2016 to 2.56 billion yuan in main business revenue. According to the top 100 list, 21 enterprises' main business revenue exceeded 10 billion yuan. Among them, Yangzijiang Pharmaceutical Group for four consecutive years in the top 100 list.
data show that Yangzijiang Pharmaceutical Group, founded in 1971, is a cross-regional, combined industry, research and development, science, industry and trade integration of large-scale national pharmaceutical enterprise groups, but also the Ministry of Science and Technology named the country's first innovative enterprises. According to data released at its year-end work conference at the end of December 2017, Yangzijiang Pharmaceutical Group's output value, sales and profits tax increased by 18.7%, 18.65% and 18.1% year-on-year in 2017.
is worth noting that Yangzijiang Pharmaceutical Group started with Chinese medicine, the proportion of Chinese medicine output value of about 25%. Among them, gastric suzu particles,bell stomach pain particles, god curly anti-oral solution and other digestive disease medication, jaundice semen oral solution, such as anti-immunity drugs, blue sulphide oral solution, Su Huang cough capsules and other upper respiratory tract infection medication has become a market star products.
Yangzijiang is just a microcosm. In recent years, the development of Chinese medicine industry in China has been developing rapidly. Data show that in the 20 years from 1996 to 2016, the Growth rate of the Chinese medicine industry reached 36 times. Among them, the size of Chinese medicine tablets increased 416 times in 20 years. In the 13th Five-Year Plan for the Development of Chinese Medicine, the Chinese medicine industry was promoted to the status of "an important pillar industry of the national economy" for the first time.
industry estimates that during the
13th Five-Year Plan" period, the main business income of enterprises above the scale of Chinese medicine will continue to maintain high growth, the scale of revenue is expected to reach 1582.3 billion yuan in 2020, the average annual growth rate will reach 15%. The proportion of income of Chinese medicine enterprises in the overall industry rose from 29.26% to 33.26%.against the trend and on the Chinese medicine innovation for a long time
It should not be ignored that, although China is increasingly attached importance to the development of Chinese medicine, but the current pace of development of Chinese medicine relative to the entire pharmaceutical industry is still lagging behind. According to the data, the growth rate of traditional medicines in 2017 was only 8.4%, far behind the average growth rate of 12.2% in the pharmaceutical industry.
In the eyes of many experts and industry insiders, the outstanding problems facing the development of the Chinese medicine industry are assotured in: the low concentration of the Chinese medicine industry, the small number of large intensive group enterprises, the manufacturing level of the Chinese medicine industry is not high, the investment in drug research and development is low, and the innovation ability is insufficient.
high cost of research and development is the primary reason why Chinese medicine companies are not expected to stop. According to Yao Zhongqing, executive vice president of the Institute of Traditional Chinese Medicine of Yangzijiang Pharmaceutical Group, the current cost of research and development of single varieties of innovative Chinese medicine drugs needs to be invested at least 50 million yuan to 100 million yuan, and the effective ingredient innovation drugs need at least 200 million yuan. Due to the large investment, the current commitment to chinese medicine innovation enterprises are not many, many pharmaceutical companies in the research and development team of Chinese medicine is shrinking.
faced with the severe situation of the pharmaceutical market, Yangzijiang Pharmaceutical Group chose to buck the trend and was named "Best Industrial Enterprise in China's Pharmaceutical Research and Development Product Line 2018" at the 2018 (35th) National Pharmaceutical Industry Information Annual Meeting.
, Yangzijiang Institute of Traditional Chinese Medicine since its establishment, and constantly develop new products. In the research of Chinese medicine innovative drug projects more than 10 items, covering cardiovascular, endocrinology, gynecology, pediatrics and digestive system. As a pioneer and leader in the industry, the Group has developed some new drugs are also expected to fill the gaps in related fields. "If the treatment of shingles, there is no effective drug, we have developed innovative Chinese medicine is about to enter Phase III clinical research, about three years can be on the market." Yao Zhongqing said.
In the "hardware" of Chinese medicine innovation, intelligent manufacturing is becoming a new trend, and Yangzijiang Pharmaceutical Group Jiangsu Longfengtang Chinese Medicine Co., Ltd. (hereinafter referred to as "Long Fengtang") is to intelligent factory as the carrier, to the key manufacturing link intelligent as the core, committed to the realization of intelligent manufacturing.
Longfengtang Chinese medicine pre-processing workshop has the country's first Chinese medicine pre-processing fully automated production linkage line;
Sun Xiaobo, director of the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences, believes that the development direction of the Chinese traditional medicine manufacturing industry must rely on technological innovation to realize the green manufacturing and intelligent manufacturing of traditional Chinese medicine, and accelerate the standardization and standardization of traditional Chinese medicine.
that Long Fengtang has been approved by the Ministry of Industry and Information Technology chinese medicine process manufacturing intelligent factory new model application project. It is expected that long Fengtang intelligent manufacturing project in 2019 will achieve phased results and pass the acceptance.multi-party efforts to accelerate the rise of expectations
Chinese medicine and Western medicine theory system is different, different treatment methods, different applicable conditions, Chinese and Western medicine complement each other has become the industry consensus. However, in the view of the industry, the development of Chinese medicine is facing more difficulties than Western medicine, and it is urgent for all parties to work together to speed up the opening of multiple intestinal obstructions.
is one of the most difficult research and development. Chinese medicine products from research and development to market cycle is very long, even up to 15 to 20 years, the investment time and cost is very high, no less than the chemical drug innovation. "For example, the endocrine drugs we are currently developing, diabetes drugs, etc., are facing extremely difficult research and development, glycogen diseases have not yet found a product with exact efficacy, we are also working on." Yao Zhongqing said that in the process of developing medicine, government support is essential. According to reports, in 2017, Yangzijiang Pharmaceuticals chinese medicine intelligent manufacturing, Chinese medicine research and development and industrialization and other major projects were approved for scientific and technological support funds of tens of millions of yuan.
the product development process, it is equally critical for all parties to work closely together on resource integration. "College talent is concentrated, focus on basic research, we focus on applied research, industrialization must rely on enterprises." Yao Zhongqing said.
chinese medicine industry is still subject to some constraints and restrictions in the pharmaceutical industry market. Yao Zhongqing admitted that the cost of research and development of Chinese medicine is not low, but it is difficult to enter the medical insurance directory, many places will also use it as an auxiliary drug, is not conducive to the innovation and promotion of Chinese medicine. "We want to expand production, but the current national health care policy and local bidding policies still have restrictions on the expansion of the share of Chinese medicine. Previously, due to the efficacy is not accurate and other issues, many Chinese medicine can not be included in therapeutic drugs, but included in complementary drugs. Future policies should be more targeted than killed with a stick. Yao Zhongqing appealed. (Economic Reference)